Abstract 1035P
Background
IMC-002 is a fully human IgG4 antibody targeting CD47. IMC-002 induces phagocytosis of tumor cells by macrophages and significantly suppresses tumor growth in preclinical models of hematologic and solid tumors. Here we present preliminary safety, pharmacokinetics (PK), and efficacy data from ongoing phase 1 study of IMC-002 in patients with advanced solid tumors who failed to standard therapy (without priming dose).
Methods
We used a traditional 3+3 design to evaluate dose limiting toxicity (DLT) over 21 days, with 4 doses of IMC-002 (5, 10, 20 and 30 mg/kg). IMC-002 was administered intravenously once every 2 weeks until disease progression or unacceptable toxicity. Tumor assessments were performed every 6 weeks according to RECIST 1.1 criteria.
Results
As of May 2023, we enrolled 12 refractory patients (9 hepatocellular carcinoma, 2 breast cancer, 1 gallbladder cancer) with median age of 55 (range 39-73). Eleven of these patients were at stage IV with multiple distant metastases and high tumor burden. The median number of prior systemic therapy was 3 (range 1-3) and 4 patients received anti-PD-(L)1 antibody. The median interval between the last dose of previous therapy and IMC-002 was 1 month (range 1-4). No DLTs were observed across 4 dose levels. The majority of treatment related adverse events (TRAEs) were grade 1-2 (92%) and most of these events occurred during the first cycle (95%). TRAEs observed in more than 2 patients included transient vitreous floaters, skin rash, anemia and nausea. No infusion related reactions, thrombocytopenia, or neutropenia were reported. The serum exposure of IMC-002 (Cmax and AUC) increased with dose, and the predicted trough concentration exceeded the minimum efficacious concentration for IMC-002 when administered at a dose of over 10 mg/kg once every 2 weeks. Among the 11 efficacy evaluable patients, 5 had stable disease with a median treatment duration of 6 cycles (range 5-12). Among them, 4 had HCC and 1 had breast cancer.
Conclusions
IMC-002 demonstrated a favorable safety profile when administered intravenously every 2 weeks up to 30 mg/kg and showed preliminary efficacy in patients with advanced solid tumors. Based on safety and PK profile, we determined the recommended phase 2 dose as 20 mg/kg.
Clinical trial identification
NCT05276310.
Editorial acknowledgement
Legal entity responsible for the study
ImmuneOncia Therapeutics, Inc.
Funding
ImmuneOncia Therapeutics, Inc.
Disclosure
H. Seon, J.K. Lee, S.Y. LEE, H.T. Kim: Financial Interests, Institutional, Full or part-time Employment: ImmuneOncia Therapeutics Inc.. All other authors have declared no conflicts of interest.
Resources from the same session
1070P - Patterns of adverse reactions for immune checkpoint inhibitors in cancer patients with central nervous system metastases
Presenter: Tianqi Gu
Session: Poster session 19
1071P - Analysis of pulmonary adverse events associated with immune checkpoint inhibitors based on FAERS and VigiBase database
Presenter: Zimu Li
Session: Poster session 19
1072P - DuoBody-EpCAMx4-1BB mediates conditional T cell co-stimulation and promotes antitumor activity in preclinical models
Presenter: Sina Fellermeier-Kopf
Session: Poster session 19
1073P - Overcoming resistance to immunotherapy with FGFR inhibition in GU cancer models
Presenter: Ilya Tsimafeyeu
Session: Poster session 19
1074TiP - A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
Presenter: Martin Gutierrez
Session: Poster session 19
1075TiP - A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors
Presenter: Ecaterina Dumbrava
Session: Poster session 19
1076TiP - First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors
Presenter: Sunil Babu
Session: Poster session 19
1077TiP - TAK-500 as a single agent and in combination with pembrolizumab in patients (pts) with advanced solid tumors: Rationale and design of a phase I/II study
Presenter: Harshabad Singh
Session: Poster session 19
1078TiP - Phase I/II, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101 (anti-VISTA) as monotherapy and in combination with cemiplimab in patients (pts) with advanced solid tumors
Presenter: Kyriakos Papadopoulos
Session: Poster session 19